A detailed history of Voya Investment Management LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Voya Investment Management LLC holds 10,385 shares of BGNE stock, worth $2.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,385
Holding current value
$2.02 Million
% of portfolio
0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$143.93 - $224.51 $1.49 Million - $2.33 Million
10,385 New
10,385 $2.33 Million
Q3 2022

Mar 03, 2023

BUY
$131.8 - $202.24 $616,428 - $945,876
4,677 New
4,677 $630,000
Q3 2022

Nov 14, 2022

SELL
$131.8 - $202.24 $15,025 - $23,055
-114 Reduced 2.38%
4,677 $631,000
Q2 2022

Aug 15, 2022

SELL
$121.11 - $216.05 $71,454 - $127,469
-590 Reduced 10.96%
4,791 $775,000
Q1 2022

May 16, 2022

BUY
$146.52 - $269.56 $95,824 - $176,292
654 Added 13.84%
5,381 $1.02 Million
Q3 2021

Nov 15, 2021

SELL
$249.6 - $403.14 $54,662 - $88,287
-219 Reduced 4.43%
4,727 $1.72 Million
Q2 2021

Aug 16, 2021

BUY
$292.75 - $367.01 $149,595 - $187,542
511 Added 11.52%
4,946 $1.7 Million
Q4 2020

Feb 16, 2021

SELL
$221.31 - $316.61 $412,521 - $590,161
-1,864 Reduced 29.59%
4,435 $1.15 Million
Q3 2020

Nov 16, 2020

BUY
$189.18 - $286.44 $50,321 - $76,193
266 Added 4.41%
6,299 $1.8 Million
Q2 2020

Aug 14, 2020

SELL
$123.9 - $195.41 $12,266 - $19,345
-99 Reduced 1.61%
6,033 $1.14 Million
Q1 2020

May 15, 2020

BUY
$121.84 - $173.19 $70,789 - $100,623
581 Added 10.47%
6,132 $755,000
Q3 2019

Nov 14, 2019

BUY
$120.61 - $148.29 $200,091 - $246,013
1,659 Added 42.63%
5,551 $680,000
Q2 2019

Aug 14, 2019

SELL
$113.99 - $146.86 $31,803 - $40,973
-279 Reduced 6.69%
3,892 $482,000
Q1 2019

May 15, 2019

BUY
$122.82 - $151.83 $25,915 - $32,036
211 Added 5.33%
4,171 $551,000
Q4 2018

Feb 14, 2019

BUY
$107.01 - $175.15 $423,759 - $693,594
3,960 New
3,960 $555,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $20.2B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.